TIDMNFX

RNS Number : 9172Z

Nuformix PLC

15 January 2020

15th January 2020

Nuformix plc

("Nuformix" or "the Group"),

Amendement to Notice

On 10 January 2020, the Group announced the receipt of Notice of Exercise 1,250,000 ordinary shares of 0.1p each in the Company (the "Warrant Shares") and that dealings in the Warrant Shares were expected to commence on 14 January 2020.

This date has now been amended such that dealings in the Warrant Shares are expected to commence on 16 January 2020.

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain. 15

Enquiries:

 
 Nuformix plc 
  Dr Dan Gooding, Chief Executive 
  Officer 
  Email: info@nuformix.com             +44 (0)1223 627222 
 
   Novum Securities Limited 
   Jon Belliss / Colin Rowbury         +44 (0)20 7399 9427

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUVSURRRUAAAR

(END) Dow Jones Newswires

January 15, 2020 07:43 ET (12:43 GMT)

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Nuformix.
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Nuformix.